Nemaura Medical Announces Interview with CEO to Air on May 11
May 05 2020 - 9:18AM
Business Wire
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on developing
micro-systems-based wearable diagnostic devices and currently
commercializing sugarBEAT®, its non-invasive and flexible
continuous glucose monitor (“CGM”), today announced an interview
with its CEO, Dr. Faz Chowdhury, will be available for viewing
beginning Monday, May 11, 2020, on RedChip Companies YouTube
channel.
In the exclusive interview, Dr. Chowdhury will provide new
insights into the Company’s previously announced head-to-head study
with a major glucose monitoring solution. The user study compares
sugarBEAT® directly against a highly successful major incumbent CGM
sensor with the goal of positioning sugarBEAT® as a non-invasive,
daily/flexible, cost-effective alternative to traditional,
expensive invasive CGM.
Several studies are planned over the course of this year
designed to demonstrate the effectiveness of intermittent use
(several non-consecutive days per week or month) of sugarBEAT® to
better manage glucose levels by increasing Time-In-Range. Dr
Chowdhury will also discuss product launch plans for Germany and
the launch of proBEAT™ in the USA.
The global total addressable market for CGM is estimated at $82
billion per annum, consisting of $12.7 billion for Type 1 insulin
users (5% of diabetes), $38.0 billion for Type 2 insulin users (15%
of diabetes) and $31.4 billion for Type 2 non-insulin users (80% of
diabetes). These numbers exclude the prediabetes population which
is estimated at nearly three times as large as the diabetes
population.
About Nemaura Medical, Inc.: Nemaura Medical Inc. (NMRD)
is a medical technology company developing micro-systems-based
wearable diagnostic devices and currently commercializing
sugarBEAT®, and proBEAT™. sugarBEAT® is a Class IIb CE marked
non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse and
prevent the onset of diabetes. People with diabetes who take
insulin can also adjunctively use sugarBEAT® for insulin dosage
purposes when calibrated by a finger stick reading. proBEAT™
comprises a prescription free non-invasive glucose monitor and a
digital healthcare subscription service planned to be launched in
the US as a general wellness product.
For more information visit: www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking Statements:
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, the launch of
proBEAT® in the US, risks related to regulatory status and the
failure of future development and preliminary marketing efforts,
Nemaura’s ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Nemaura and its
partners’ ability to develop, market and sell proBEAT®, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to both
proBEAT® digital health, and sugarBEAT®. There can be no assurance
that the company will be able to reach a part of or any of the
global market for CGM with its products/services. The FDA reserves
the right to re-evaluate their decision that proBEAT® qualifies as
a general wellness product should it become aware of any issues
such as skin irritation or other adverse events from the device, as
well as any misuse impacting patient safety, and any other reason
as the FDA may see fit at its discretion to determine the product
does not fit the definition of a general wellness product. These
and other risks and uncertainties are identified and described in
more detail in Nemaura’s filings with the United States Securities
and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the most recently completed fiscal year,
its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200505005635/en/
Investor Contact: Dave Gentry, CEO RedChip Companies
Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498
dave@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024